{"nctId":"NCT00151775","briefTitle":"Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure","startDateStruct":{"date":"2005-05"},"conditions":["Hypertension"],"count":362,"armGroups":[{"label":"Period 2","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil"]},{"label":"Period 3","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil","Drug: placebo"]},{"label":"Period 4","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil"]}],"interventions":[{"name":"olmesartan medoxomil","otherNames":["Benicar (olmesartan medoxomil)"]},{"name":"placebo","otherNames":[]},{"name":"olmesartan medoxomil","otherNames":["Benicar (olmesartan medoxomil)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient's seated systolic BP (SeSBP) will be greater than or equal to 95th percentile for gender and height-for- age, or greater than or equal to 90th percentile if the patient is diabetic, or has glomerular kidney disease, or has a family history of hypertension.\n* Negative for hepatitis B and C\n* Negative for HIV\n\nExclusion Criteria:\n\n* Patient should not have serious other conditions that could interfere with the analysis of the results or that could interfere with the well-being of the patient in the trial.\n* Known sensitivity to olmesartan medoxomil\n* Taking prohibited medication\n* Consumed greater than 180 mg of caffeine daily\n* Malignant hypertension\n* History of congestive heart failure, cardiomyopathy, or obstructive valve disease\n* Renal transplant within the previous 6 months\n* Severe nephritic syndrome not in remission","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)","description":"The efficacy dose response change in trough seated systolic blood pressure (both non-weight adjusted and weight adjusted results) from baseline to the end of the dose-ranging period (Period 2). Non-weight adjusted dose was the fixed olmesartan medoxomil dose; weight adjusted dose calculated mg of olmesartan medoxomil per kg of weight at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"0.202"},{"groupId":"OG001","value":"-0.85","spread":"0.282"},{"groupId":"OG002","value":"-0.75","spread":"0.165"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.97","spread":"2.054"},{"groupId":"OG001","value":"-7.17","spread":"3.190"},{"groupId":"OG002","value":"-8.36","spread":"1.750"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks)","description":"Mean change from baseline to the end of the dose ranging period in systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.76","spread":"9.180"},{"groupId":"OG001","value":"-12.58","spread":"10.157"},{"groupId":"OG002","value":"-4.73","spread":"11.483"},{"groupId":"OG003","value":"-10.68","spread":"9.259"},{"groupId":"OG004","value":"-6.63","spread":"10.170"},{"groupId":"OG005","value":"-11.87","spread":"9.843"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.52","spread":"8.058"},{"groupId":"OG001","value":"-9.50","spread":"9.757"},{"groupId":"OG002","value":"-3.49","spread":"8.844"},{"groupId":"OG003","value":"-7.58","spread":"8.172"},{"groupId":"OG004","value":"-4.76","spread":"8.389"},{"groupId":"OG005","value":"-8.78","spread":"9.216"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3","description":"Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"9.46"},{"groupId":"OG001","value":"4.93","spread":"9.62"},{"groupId":"OG002","value":"1.37","spread":"9.50"},{"groupId":"OG003","value":"3.79","spread":"10.00"},{"groupId":"OG004","value":"0.77","spread":"9.451"},{"groupId":"OG005","value":"4.50","spread":"9.745"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"8.12"},{"groupId":"OG001","value":"4.43","spread":"10.15"},{"groupId":"OG002","value":"1.94","spread":"7.10"},{"groupId":"OG003","value":"3.25","spread":"8.74"},{"groupId":"OG004","value":"0.85","spread":"7.790"},{"groupId":"OG005","value":"3.99","spread":"9.627"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3","description":"Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort C.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":"8.994"},{"groupId":"OG001","value":"4.95","spread":"8.568"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"8.556"},{"groupId":"OG001","value":"3.77","spread":"7.203"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)","description":"Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.8","spread":"9.75"},{"groupId":"OG001","value":"-7.7","spread":"12.71"},{"groupId":"OG002","value":"-9.7","spread":"11.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"9.31"},{"groupId":"OG001","value":"-5.1","spread":"9.45"},{"groupId":"OG002","value":"-6.6","spread":"9.41"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)","description":"Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort C.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.7","spread":"9.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.3","spread":"11.18"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":95},"commonTop":["Headache","Upper respiratory tract infection","Cough","Pyrexia","Nasopharyngitis"]}}}